What Institut Pasteur de Montevideo does

Institut Pasteur de Montevideo is a Uruguayan non-profit scientific research institute established in 2006 through a cooperation agreement between the governments of Uruguay and France, and operates as a member of the International Network of Pasteur Institutes (RIIP), which spans 33 institutions across five continents. The institute is headquartered on a 23,000 m2 campus in Malvín Norte, Montevideo, housing more than 25 laboratories and technological units staffed by 200+ researchers ranging from students to principal investigators. Core research areas include genomics, oncology, immunology, drug control, crystallography, neuroscience, bioinformatics, and bioimaging, with dedicated platforms such as the Advanced Bioimaging Unit (ABU), the UBAL laboratory animal biotechnology unit (maintaining 10,000+ mice), and the Proteomics and Analytical Biochemistry Unit.

The institute has built a portfolio of proprietary and differentiated technologies, including REJOIN-seq for restoring and analyzing partially degraded cell-free RNA, stem-cell-derived organoid and mini-intestine generation platforms, single-tube qPCR with internal controls for SARS-CoV-2 variant surveillance, and CRISPR-based genome editing for laboratory animal model creation. These capabilities have been validated externally through peer-reviewed publications, coverage in Nature, and recognitions such as Nature's 10 (Gonzalo Moratorio, 2020) and the Académie Vétérinaire de France's first South American woman member (Martina Crispo, 2022). During the COVID-19 pandemic the institute acted as Uruguay's principal domestic developer of PCR and serological diagnostics, producing 50,000+ PCR kits and 350,000+ serological kits distributed nationally and regionally.

IP Montevideo's business model is non-commercial and grant-driven. Recurring revenue streams include core institutional funding from the Uruguayan government, founding support from the French government, European Union and multilateral development bank financing (notably FOCEM and IDB), and private philanthropy (notably from the Chan Zuckerberg Initiative, totaling roughly US$870K across 2020-2021). Commercial income derives from fee-for-service laboratory work, technology platform access (bioimaging, bioterio, proteomics, bioinformatics), and venture-building economics through LAB+ Venture Builder, which received an US$35 million eight-year commitment from Ficus Advisory in 2021 to spin out life-sciences companies from institute research. Customer segments span academic and government research institutions (primary), biotech and pharmaceutical companies seeking specialized services, the regional startup ecosystem via LAB+, and educational institutions reached through extensive scientific outreach. Pricing is not publicly disclosed and services are negotiated per engagement or via collaborative agreements.

Name

Institut Pasteur de Montevideo

Legal name

Institut Pasteur de Montevideo

Website

https://pasteur.uy

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

101–250 employees

Short description

Institut Pasteur de Montevideo is a Uruguayan non-profit biomedical research institute operating 25+ laboratories and 200+ researchers across genomics, immunology, neuroscience, and bioinformatics, serving academic, government, and biotech clients with the support of the Pasteur Network.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

Keywords

• Biomedical research services
• Genomics research
• Bioimaging services
• Diagnostic kit production
• Scientific training programs

Headquarters

HQ city

Montevideo

HQ country

Uruguay

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Government Funding (Uruguay): Core institutional funding from the Uruguayan government as part of the national scientific-technological system
2. International Cooperation Funding: Funding from French government, European Union, and international development banks (IDB, FOCEM) for research projects and infrastructure
3. Private Philanthropy: Grants from organizations like Chan Zuckerberg Initiative for specific research programs and equipment
4. Venture Capital (LAB+ Venture Builder): US$ 35 million venture builder fund managed by Ficus Advisory to support spin-off companies from institute research
5. Technological Services: Fee-for-service laboratory operations including bioterio services, diagnostic kit production, and scientific equipment access
6. FOCEM Regional Funding: Over US$ 1 million in recent equipment purchases from Mercosur convergence fund for infrastructure and technology

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Institut Pasteur de Montevideo is a non-profit biomedical research institute that conducts fundamental and applied research across genomics, oncology, immunology, neuroscience, bioinformatics, and infectious diseases. It delivers technological services through specialized units (Advanced Bioimaging, UBAL laboratory animal biotechnology, Bioinformatics, Proteomics), develops proprietary platforms such as REJOIN-seq for cell-free RNA analysis and organoid generation, and produces diagnostic kits. It also runs the LAB+ Venture Builder for life-sciences startup creation and offers scientific training and outreach programs.

Product overview

Institut Pasteur de Montevideo is a research institute offering integrated scientific research and technological services through specialized units including Advanced Bioimaging, Biotechnology, Bioinformatics, and Proteomics. The institute provides technology platforms such as REJOIN-seq for cell-free RNA analysis and an organoid generation platform for disease modeling. It develops diagnostic products including COVID-19 tests, supports innovation through its LAB+ Venture Builder program, and offers educational programs. The portfolio is organized around core research services enhanced by dedicated technological platforms and innovation support.

Differentiator

Problem solved

Functional benefit

Brands

• LAB+ Venture Builder: An initiative promoted by Institut Pasteur de Montevideo with financial contribution from Ficus Advisory to transform high-potential research projects into international sustainable companies in the life sciences sector.
• LAB+
• Amigos Pasteur
• Sentimiento Bacteriano

Products and services

• Advanced Bioimaging Unit (ABU) Provides advanced microscopy and biophotonics services including multiphoton microscopy, fluorescence lifetime imaging (FLIM), deep-tissue imaging, and intravital metabolic imaging for academic and clinical researchers in Uruguay and the region.
• UBAL - Laboratory Animal Biotechnology Unit Generates genetically modified mice through CRISPR and other genome-editing technologies, provides cryopreservation of embryos, and supplies laboratory animal models to researchers in Uruguay and abroad.
• REJOIN-seq Technology Platform Proprietary cell-free RNA (cfRNA) restoration and analysis technology that enables recovery of partially degraded cfRNA samples for biomarker and disease-mechanism research, offered for collaboration with biotech companies such as Resolve Therapeutics.
• Organoid and Mini-Intestine Generation Platform Stem cell-derived organoid models (including mini-intestines) used to study intestinal diseases, Chagas disease, and other conditions for academic researchers and pharmaceutical partners.
• COVID-19 Diagnostic Kit Production Locally developed and validated molecular and serological SARS-CoV-2 diagnostic test kits, distributed through Uruguay's Ministry of Public Health and to neighboring Mercosur countries.
• LAB+ Venture Builder Venture-building program providing management support, infrastructure, financing, and know-how to spin off life-sciences companies from IP Montevideo research in the One Health domain.
• Scientific Training Courses and Seminars Structured training courses and an ongoing seminar series targeting graduate students, researchers, and clinicians from Uruguay and the Latin American region.

Quantifiable outcome

• 87% reduction in plaque titration analysis time through Titra collaboration
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

16 partnerships are on record, tiered core and minor.

• Resolve TherapeuticscoreStrategic or Co-development Partner · 7 April 2026Collaboration to use REJOIN-seq technology for identifying cell-free RNA molecules that trigger inflammation in autoimmune diseases such as lupus and Sjögren's. The technology developed at Institut Pasteur de Montevideo can restore and repair partially degraded cfRNA that conventional sequencing methods fail to capture, enabling analysis of disease-related molecules previously lost.
• ArionkoderminorStrategic or Co-development Partner · 19 February 2026Co-designed Titra with the Pasteur Institute of Montevideo, a solution that reduced plaque titration analysis time by 87%. Arionkoder is an AI consulting firm that showcased this collaboration at ViVE 2026 healthcare conference.
• Latin American Bioimaging (LABI)coreStrategic or Co-development Partner · 16 November 2021Regional bioimaging network coordinated by Andrés Kamaid (IP Montevideo) together with partners in Brazil (Federal University of Rio de Janeiro) and Argentina (University of Buenos Aires). CZI-funded for network consolidation.
• Center for Structural Biology of Mercosur (CeBEM)coreStrategic or Co-development Partner · 16 November 2021South American network co-led by Alejandro Buschiazzo (IP Montevideo) with nodes in Argentina and Brazil. Aims to associate Structural Biology and Bioimaging across Latin America with CZI support.
• ATGencoreTechnology or Integration · 3 August 2020Developed and validated national serological test for COVID-19 together with IP Montevideo, Udelar faculties. ATGen contributes expertise in test kit production and commercialization.
• Institut Pasteur in PariscoreStrategic or Co-development PartnerFounding partner of IP Montevideo through cooperation agreement between Uruguay and France. Part of the International Network of Pasteur Institutes (RIIP) connecting 33 institutions globally.
• University of the Republic (Udelar)coreStrategic or Co-development PartnerKey institutional partner with collaboration across multiple faculties including Sciences, Medicine, Chemistry. Joint units like Advanced Bioimaging Unit operate between IP Montevideo and Udelar Hospital de Clínicas.
• International Network of Pasteur Institutes (RIIP)coreOthersGlobal network associating 33 independent institutions located on five continents, united by the same culture and values. Provides framework for international collaboration and knowledge sharing.
• OncoRx (Colorado Health Startup)minorStrategic or Co-development PartnerPrecision oncology case study showcased by Arionkoder at ViVE 2026 demonstrating AI applications in healthcare.
• iSono HealthminorStrategic or Co-development PartnerHealthcare AI company achieving 28.7% reduction in false detections in breast cancer scanning, case study presented at ViVE 2026.
• Inter Institutional Working Group on Genomic Surveillance of SARS-CoV-2 (GTi)coreStrategic or Co-development PartnerWorking group comprising researchers from IP Montevideo, Republic University, Sanatorio Americano, ATGen, and Ministry of Public Health for real-time SARS-CoV-2 genomic monitoring.
• Latinbiota ConsortiumcoreStrategic or Co-development PartnerScientific consortium spanning 12+ Latin American countries (Uruguay, Argentina, Chile, Bolivia, Brazil, Colombia, Ecuador, Mexico, Paraguay, Costa Rica, Peru, French Guiana) gathering microbiome data.
• Ministry of Public Health (Uruguay)coreOthersCoordination partner for distribution of serological tests and recipient of genomic surveillance reports for national health planning.
• LAB+ Venture Builder PartnersminorStrategic or Co-development PartnerFicus Advisory-led venture builder structure offering management support, infrastructure, and financing for research-based startup creation in life sciences.
• ICGEB, UNU-Biolac, Pasteur NetworkminorStrategic or Co-development PartnerInternational organizations providing support for training courses and enabling regional student participation in UBAL educational programs.
• GenLivesminorOthersStartup founded by IP Montevideo researchers including Lucía Spangenberg to provide genome sequencing access for people with rare diseases.

Scale indicators17 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• European Molecular Biology Laboratory (EMBL): Intergovernmental research organization operating multiple sites across Europe providing structural biology, bioimaging, and bioinformatics services. Comparable in offering shared technology platforms (such as ABU equivalent) to national scientific communities.
• Wellcome Sanger Institute: UK-based genomics and bioinformatics research institute with comparable headcount scale and a model of operating multiple technology platforms for the research community. Useful benchmark for translational bioinformatics and platform-services operations.
• Institut Pasteur (Paris): The founding member and namesake of the Pasteur Network, headquartered in Paris with vastly larger scale across all biomedical disciplines. Functions as the network's anchor and founding partner of IP Montevideo, providing governance, training, and scientific reputation.
• Broad Institute of MIT and Harvard: Much larger US-based biomedical and genomic research institute, but architecturally similar in blending core labs, technology platforms, and translational programs. Relevant benchmark for how platform-and-startup models scale.
• Howard Hughes Medical Institute (HHMI) Janelia Research Campus: US research campus operating shared advanced-imaging and technology platforms for visiting scientists, mirroring IP Montevideo's Advanced Bioimaging Unit (ABU) model of providing cutting-edge microscopy as a service.

Emerging players

• Chan Zuckerberg Biohub: Non-profit biomedical research organization funded by CZI to build large-scale technology platforms in imaging and cell biology. Direct source of much of IP Montevideo's CZI funding and overlapping focus on advanced bioimaging infrastructure.

Direct peers

• Institut Pasteur de Lille: A sister Pasteur Network institute in France of comparable size and structure, focused on public health, infectious diseases, and translational research. Highly comparable organizational model and research portfolio to IP Montevideo.
• Fundação Oswaldo Cruz (Fiocruz): Brazil's leading public biomedical research institute and a FOCEM regional partner with IP Montevideo. Operates across infectious disease, genomics, and biotechnology with comparable mission and scale, making it the closest functional peer in Latin America.
• Fundación Instituto Leloir: Argentina's premier private biomedical research institute in Buenos Aires, conducting similar multidisciplinary research in genomics, structural biology, and neuroscience, with comparable size and academic affiliation patterns.
• Instituto de Investigaciones Bioquímicas de Buenos Aires (IBioBA, CONICET): Argentine biomedical research institute partnering with IP Montevideo under the FOCEM Biomedical Research Network alongside Fiocruz and Paraguayan institutes. Comparable in focus on molecular biology, neuroscience, and translational research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/IPMontevideo
• YouTubeyoutube.com/channel/UCb2Hnt_H-_f9ah3jfr0z1rQ
• Facebookfacebook.com/IPMontevideo
• LinkedInlinkedin.com/company/ipmontevideo
• Instagraminstagram.com/institutpasteurmontevideo

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut Pasteur de Montevideo